inhaled p38α/β MAPK inhibitor
effective in the rat LPS-induced lung inflamm. model
SBDD and focus on slow dissociation kinetics
J. Med. Chem.
Chiesi Farmaceutici, Parma, IT
Context. “compound 4e” (Chiesi Farmaceutici) is an inhaled p38α/β mitogen-activated protein kinase (MAPK) inhibitor being developed for lung inflammatory diseases. As a regulator of key proinflammatory mediators, p38 MAPK…